CN115315439A - 细胞 - Google Patents

细胞 Download PDF

Info

Publication number
CN115315439A
CN115315439A CN202180023261.3A CN202180023261A CN115315439A CN 115315439 A CN115315439 A CN 115315439A CN 202180023261 A CN202180023261 A CN 202180023261A CN 115315439 A CN115315439 A CN 115315439A
Authority
CN
China
Prior art keywords
fas
cells
seq
domain
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023261.3A
Other languages
English (en)
Chinese (zh)
Inventor
C.麦肯齐
S.科多巴
M.普勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2005331.0A external-priority patent/GB202005331D0/en
Priority claimed from GBGB2017358.9A external-priority patent/GB202017358D0/en
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of CN115315439A publication Critical patent/CN115315439A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
CN202180023261.3A 2020-04-09 2021-04-08 细胞 Pending CN115315439A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2005331.0 2020-04-09
GBGB2005331.0A GB202005331D0 (en) 2020-04-09 2020-04-09 Cell
GB2017358.9 2020-11-02
GBGB2017358.9A GB202017358D0 (en) 2020-11-02 2020-11-02 Cell
PCT/GB2021/050866 WO2021205176A2 (en) 2020-04-09 2021-04-08 Cell

Publications (1)

Publication Number Publication Date
CN115315439A true CN115315439A (zh) 2022-11-08

Family

ID=75539696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023261.3A Pending CN115315439A (zh) 2020-04-09 2021-04-08 细胞

Country Status (7)

Country Link
US (1) US20230113183A1 (cg-RX-API-DMAC7.html)
EP (1) EP4132963A2 (cg-RX-API-DMAC7.html)
JP (2) JP7755597B2 (cg-RX-API-DMAC7.html)
CN (1) CN115315439A (cg-RX-API-DMAC7.html)
AU (1) AU2021253759A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174812A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021205176A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
JP2024541501A (ja) * 2021-11-25 2024-11-08 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ Cd95ポリペプチド
EP4476246A4 (en) * 2022-02-07 2026-05-13 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Recombinant proteins that stimulate an immune response in the presence of a naturally inhibitory ligand bond

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240483A1 (en) * 2001-10-14 2006-10-26 Hartmut Engelmann Method and kit for monitoring recruitment of proteins to the intracellular domain of a receptor in intact cells
US20100303811A1 (en) * 2008-06-16 2010-12-02 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
US20180118838A1 (en) * 2015-09-23 2018-05-03 Precision Immunotherapy, Inc. Flt3 directed car cells for immunotherapy
WO2019073248A1 (en) * 2017-10-12 2019-04-18 Autolus Limited CELL
WO2019116046A1 (en) * 2017-12-15 2019-06-20 Autolus Limited Cell
US20200009190A1 (en) * 2017-03-17 2020-01-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
US20210363217A1 (en) * 2018-06-19 2021-11-25 Autolus Limited Cell
EP3856769A4 (en) * 2018-09-28 2022-08-17 Memorial Sloan Kettering Cancer Center IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240483A1 (en) * 2001-10-14 2006-10-26 Hartmut Engelmann Method and kit for monitoring recruitment of proteins to the intracellular domain of a receptor in intact cells
US20100303811A1 (en) * 2008-06-16 2010-12-02 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
US20180118838A1 (en) * 2015-09-23 2018-05-03 Precision Immunotherapy, Inc. Flt3 directed car cells for immunotherapy
US20200009190A1 (en) * 2017-03-17 2020-01-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2019073248A1 (en) * 2017-10-12 2019-04-18 Autolus Limited CELL
WO2019116046A1 (en) * 2017-12-15 2019-06-20 Autolus Limited Cell

Also Published As

Publication number Publication date
EP4132963A2 (en) 2023-02-15
JP7755597B2 (ja) 2025-10-16
US20230113183A1 (en) 2023-04-13
JP2023521330A (ja) 2023-05-24
CA3174812A1 (en) 2021-10-14
AU2021253759A1 (en) 2022-09-01
WO2021205176A2 (en) 2021-10-14
WO2021205176A3 (en) 2021-11-11
JP2025170345A (ja) 2025-11-18

Similar Documents

Publication Publication Date Title
US12624088B2 (en) Chimeric receptor comprising a ligand binding domain and an endodomain comprising a cytokine receptor endodomain and an intracellular T cell signalling domain
US12187769B2 (en) Cell
AU2016272457B2 (en) Cell
US11643453B2 (en) Cell
EP3724320B1 (en) Cell
CN107922951B (zh) 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体
JP2025170345A (ja) 細胞
WO2021048564A2 (en) Antigen-binding domain
JP6842688B2 (ja) キメラ抗原受容体
WO2022167798A1 (en) Molecule
JP7054181B2 (ja) キメラ抗原受容体
KR20260052956A (ko) TGFβ 스위치 수용체, 이를 코딩하는 핵산, 이를 포함하는 세포 및 약학 조성물
NZ737662B2 (en) Cell

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination